82 related articles for article (PubMed ID: 709936)
1. Interim report on treatment of osteoporotic patients with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):232-40. PubMed ID: 709936
[TBL] [Abstract][Full Text] [Related]
2. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Eriksson S; Lindholm TC
Ital J Orthop Traumatol; 1984 Jun; 10(2):187-201. PubMed ID: 6432736
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis].
Yoshikawa S; Ohno A; Moro K; Matsumoto M; Nemoto H; Seki H; Kaneko N; Hosokawa O; Ishijima H
Nihon Seikeigeka Gakkai Zasshi; 1988 Aug; 62(8):723-32. PubMed ID: 3235892
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
7. Reduced parathyroid hormone response to peroral phosphate in osteoporotic patients.
Ittner J; Dambacher MA; Muff R; Rüegsegger P; Trechsel U; Fischer JA
Miner Electrolyte Metab; 1986; 12(3):199-203. PubMed ID: 3014300
[TBL] [Abstract][Full Text] [Related]
8. [Calciotropic hormones in osteoporosis caused by anorexia nervosa].
Saggese G; Bertelloni S; Baroncelli GI; Ghirri P; Cosenza GM; Buggiani B
Minerva Pediatr; 1989 Feb; 41(2):61-5. PubMed ID: 2786986
[TBL] [Abstract][Full Text] [Related]
9. Percent true calcium absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with vitamin D3 and calcium.
Hillman LS; Cassidy JT; Chanetsa F; Hewett JE; Higgins BJ; Robertson JD
Arthritis Rheum; 2008 Oct; 58(10):3255-63. PubMed ID: 18821668
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Eriksson S
Scand J Rheumatol; 1982; 11(1):55-7. PubMed ID: 7063813
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
12. Preventive treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium. Evaluation of bone histomorphometry in osteoporotics and age matched controls.
Lindholm TS; Nilsson OS; Widhe T; Elmsted E; Eriksson S
Acta Vitaminol Enzymol; 1982; 4(1-2):179-84. PubMed ID: 7124565
[No Abstract] [Full Text] [Related]
13. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
14. Alfacalcidol (alpha D3) and calcium in osteoporosis.
Menczel J; Foldes J; Steinberg R; Leichter I; Shalita B; Bdolah-Abram T; Kadosh S; Mazor Z; Ladkani D
Clin Orthop Relat Res; 1994 Mar; (300):241-7. PubMed ID: 8131343
[TBL] [Abstract][Full Text] [Related]
15. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
[TBL] [Abstract][Full Text] [Related]
16. A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study.
Cohen HN; Farrah D; Fogelman I; Goll CC; Beastall GH; McIntosh WB; Fletcher M; Boyle IT
Clin Endocrinol (Oxf); 1980 Jun; 12(6):537-42. PubMed ID: 7398099
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
18. [Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis].
Yamada H
Nihon Naibunpi Gakkai Zasshi; 1989 Jun; 65(6):603-14. PubMed ID: 2792461
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of 1-alpha-hydroxy-vitamin D3 in patients on corticosteroid treatment and in patients with senile osteoporosis.
Lindgren U; Lindholm S; Sarby B
Acta Med Scand; 1978; 204(1-2):89-92. PubMed ID: 685736
[TBL] [Abstract][Full Text] [Related]
20. [Effect of cortisone on calcium metabolism. Attempt at correction by 5,6 trans 25-hydroxycholecalciferol, 25-hydroxycholecalciferol and vitamin D2].
Miravet L; Gueris J; Rousselet F; Ryckewaert A
Nouv Presse Med; 1977 May; 6(21):1847-51. PubMed ID: 301629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
